Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc. (symbol: RBOT) is at the forefront of innovation in the field of surgical robotics. The company is dedicated to enhancing the capabilities of surgeons and improving patient outcomes through advanced technological solutions. Vicarious Surgical has developed a unique surgical robot that combines human-like dexterity with the world's first virtual-reality surgical camera, enabling surgeons to perform minimally invasive procedures with the same ease as traditional open surgery.
The company’s flagship product, the Vicarious Surgical Robotic System, is specifically designed for abdominal surgeries. It offers 3D visualization and precise control, all through a single port, which significantly reduces the invasiveness of surgical procedures. This groundbreaking technology aims to expand global access to high-quality surgical care.
Vicarious Surgical's approach redefines what is possible in surgical robotics by integrating cutting-edge virtual reality and robotics technology. The company has achieved significant milestones in recent years, including key partnerships and notable advancements in their robotic systems.
Financially, Vicarious Surgical continues to show promise with robust investments and strategic collaborations that drive its growth and innovation. The company remains committed to pushing the boundaries of medical technology, with ongoing projects focused on further enhancing their systems and expanding their applications.
For investors and stakeholders, Vicarious Surgical represents a compelling opportunity in the rapidly evolving field of medical technology. The company’s mission to improve surgical outcomes and patient care through revolutionary robotics sets it apart as a leader in the industry.
Stay updated with the latest news and developments from Vicarious Surgical to understand its impact and progress in the surgical robotics landscape.
Vicarious Surgical (NYSE: RBOT) announced that Chief Financial Officer William Kelly will be departing the company on January 2, 2025. Kelly, who has served as CFO since January 2021, is leaving to pursue other career opportunities after nearly four years with the company.
Kelly will assist in ensuring a smooth transition of responsibilities before his departure. The company has initiated a CFO succession process and will provide updates accordingly. CEO Adam Sachs expressed gratitude for Kelly's significant contributions during his tenure.
Vicarious Surgical announced its Q3 2024 financial results. Operating expenses decreased by 17% to $17.8M from $21.4M in Q3 2023. R&D expenses dropped to $10.8M from $13.0M, general and administrative expenses fell to $5.7M from $6.9M, and sales and marketing expenses decreased to $1.2M from $1.4M. The adjusted net loss was $17.0M, or $2.87 per share, compared to $20.4M, or $3.95 per share, in the same period last year. GAAP net loss was $17.1M, or $2.90 per share, versus $15.7M, or $3.04 per share, last year. The company had $60.9M in cash and investments as of September 30, 2024, with a Q3 cash burn rate of $12.4M. Full-year 2024 cash burn is expected to be approximately $50M. CEO Adam Sachs highlighted the upcoming milestone for the Version 1.0 System integration and the goal to complete the first clinical patient within a year.
Vicarious Surgical (NYSE: RBOT) has announced it will release its third quarter 2024 financial results on November 12, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can join via phone by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) using access code 246564. A webcast will be available on the company's investor relations website.
Vicarious Surgical Inc. (NYSE: RBOT), a pioneering robotics technology company focused on revolutionizing robotic surgery, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management team is set to engage in a fireside chat on Friday, September 6, 2024, at 11:30 a.m. ET.
This presentation at a major healthcare conference highlights Vicarious Surgical's commitment to showcasing its innovative approach to improving surgical procedures through advanced robotics. The company's participation provides an opportunity for investors and industry professionals to gain insights into Vicarious Surgical's technology and future plans in the rapidly evolving field of robotic-assisted surgery.
Vicarious Surgical Inc. (NYSE: RBOT), a next-generation robotics technology company, reported its Q2 2024 financial results. The company is on track to achieve its V1.0 integration milestone this fall and aims for its first clinical patient around this time next year. Key highlights include:
- Partnership agreement with LSU Health New Orleans, the fifth U.S. hospital system to partner with Vicarious Surgical
- Operating expenses decreased by 17% to $17.7 million
- Adjusted net loss of $16.8 million ($2.86 per share)
- GAAP net loss of $15.2 million ($2.59 per share)
- Cash and investments of $73.2 million as of June 30, 2024
- Q2 2024 cash burn rate of $10.9 million
- Full year 2024 cash burn guidance reiterated at approximately $50 million
Vicarious Surgical (NYSE: RBOT) has signed a strategic development agreement with LSU Health New Orleans, Louisiana's flagship academic health sciences center. This partnership will provide Vicarious Surgical access to LSU Health's network of experienced robotic surgeons and supporting staff. The collaboration aims to validate training protocols and identify drivers of surgeon adoption for Vicarious Surgical's V1.0 system.
LSU Health New Orleans, which partners with University Medical Center (UMC), treats over 200,000 patients annually and is responsible for more than 1 million patient visits across its broader system. The partnership will allow Vicarious Surgical to conduct formative studies on the clinical and economic value of their system, particularly in regional care settings with an academic focus.
Vicarious Surgical Inc. (NYSE: RBOT), a next-generation robotics technology company focused on improving surgical robotics, has announced its plans to report second quarter 2024 financial results on August 12, 2024, after the market closes. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can participate in the call by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) using the access code 997268. Additionally, a live and archived webcast of the event will be available on the company's investor relations website.
Vicarious Surgical (NYSE: RBOT, RBOT WS) announced a 1-for-30 reverse stock split for its Class A and Class B common stock, effective June 12, 2024. This move aims to raise the company's share price to meet NYSE listing requirements. Post-split, Class A common stock will reduce from approximately 156.76 million to about 5.23 million shares, and Class B from 19.62 million to roughly 654,000 shares. Trading on a post-split basis begins on June 13, 2024, under the symbol 'RBOT'. The split will uniformly affect all stockholders without changing ownership percentages, except for fractional shares, which will be paid in cash. Warrants will also be adjusted, with the exercise price changing to $345 per share.
Vicarious Surgical Inc. (RBOT) reported its first-quarter 2024 financial results, showcasing a decrease in operating expenses, R&D expenses, general and administrative expenses, and sales and marketing expenses compared to the previous year. The company reported an adjusted net loss of $15.1 million, equating to a loss of $0.09 per share, and a GAAP net loss of $17.0 million, or a net loss per share of $0.10 for the same period. Vicarious Surgical had $84.1 million in cash and investments as of March 31, 2024, with a cash burn rate of $14.1 million for the first quarter. The company reiterated its expected full-year 2024 cash burn of approximately $50 million.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
What does Vicarious Surgical Inc. specialize in?
What is the Vicarious Surgical Robotic System?
How does Vicarious Surgical's technology benefit surgeons?
What makes Vicarious Surgical's approach unique?
Where can I find the latest news about Vicarious Surgical Inc.?
What are the recent achievements of Vicarious Surgical Inc.?
How does the Vicarious Surgical Robotic System improve patient outcomes?
Is Vicarious Surgical Inc. involved in any partnerships?
What is the focus area of Vicarious Surgical's robotic system?
How does Vicarious Surgical's technology expand global access to surgical care?
